# Phase 1 Renal Insufficiency, Chronic trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 1 for Renal Insufficiency, Chronic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Renal Insufficiency, Chronic trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/renal-insufficiency-chronic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07924930 | A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney Function | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | Phase 1 | Not yet recruiting | Renal Insufficiency, Healthy Participant | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924930) |
| October 28, 2026 | NCT07901933 | Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease | Cajal Therapeutics Inc. | Phase 1 | Not yet recruiting | Chronic Kidney Disease, Anemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901933) |
| September 9, 2026 | NCT07808788 | A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced... | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Chronic Kidney Disease | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808788) |
| August 12, 2026 | NCT07759167 | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | Regeneron Pharmaceuticals | Phase 1 | Recruiting | End-Stage Kidney Disease (ESKD) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759167) |
| August 3, 2026 | NCT07741136 | Pharmacokinetics of Zoledronic Acid in Patients on Dialysis | University of Campinas, Brazil | Phase 1 | Not yet recruiting | Chronic Kidney Disease, Osteoporosis, Dialysis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741136) |
| July 16, 2026 | NCT07708038 | Anti-Interleukin-6 (IL6) in Calciphylaxis | Boston Medical Center | Phase 1 | Not yet recruiting | Calciphylaxis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708038) |
| July 10, 2026 | NCT07694544 | Renal Impairment Study for Oral EC5026 | EicOsis Human Health Inc. | Phase 1 | Recruiting | Chronic Kidney Disease | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694544) |
| June 1, 2026 | NCT07619157 | A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus | Ono Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Type2 Diabetes Mellitus, Chronic Kidney Disease | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619157) |
| May 29, 2026 | NCT07615985 | Phase 1a Study Assessing Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016 | Pulmongene Ltd. | Phase 1 | Recruiting | Chronic Kidney Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615985) |
| May 7, 2026 | NCT07572890 | Adia Med of Winter Park LLC Chronic Kidney Disease Research Study | Adia Med of Winter Park LLC | Phase 1 | Recruiting | Chronic Kidney Disease, Kidney Disease, Kidney Disease, Chronic, Chronic Kidney Disease (CKD), CKD | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572890) |
| April 29, 2026 | NCT07557407 | A Mass Balance Study of \[14C\]HRS-1780 in Healthy Adult Male Subjects | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Chronic Kidney Diseases | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557407) |
| March 19, 2026 | NCT07483372 | Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney... | The First Affiliated Hospital with Nanjing Medical University | Phase 1 | Recruiting | Resistant Arterial Hypertension, Chronic Kidney Disease (Stage 3-4) | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483372) |
| December 10, 2025 | NCT07275788 | A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) | Regend Therapeutics | Phase 1 | Recruiting | Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07275788) |
| December 3, 2025 | NCT07262333 | A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Recruiting | Renal Insufficiency Chronic | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262333) |
| November 19, 2025 | NCT07235059 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease | Novartis Pharmaceuticals | Phase 1 | Recruiting | Chronic Kidney Disease | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235059) |
| August 27, 2025 | NCT07143331 | A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers | Klotho Sciences Australia Pty Ltd. | Phase 1 | Not yet recruiting | Healthy Participants, Alzheimer Disease, Chronic Kidney Disease | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07143331) |
| July 8, 2025 | NCT07054684 | Study of BHV-1400 in IgA Nephropathy | Biohaven Therapeutics Ltd. | Phase 1 | Recruiting | IgA Nephropathy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07054684) |
| July 1, 2025 | NCT07045467 | Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study | Qianfoshan Hospital | Phase 1 | Recruiting | Chronic Kidney Diseases, Renal Transplantation | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07045467) |
| June 17, 2025 | NCT07024823 | A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes... | AstraZeneca | Phase 1 | Recruiting | Chronic Kidney Disease | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024823) |
| June 13, 2025 | NCT07021157 | A Study to Evaluate the Safety, Tolerability and PK of SK-08 | Consun Pharmaceutical Group | Phase 1 | Recruiting | Chronic Kidney Disease(CKD) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07021157) |
| December 18, 2024 | NCT06741072 | BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ... | Ohio State University Comprehensive Cancer Center | Phase 1 | Recruiting | Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06741072) |
| September 1, 2022 | NCT05525507 | Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants | University of California, Los Angeles | Phase 1 | Recruiting | End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05525507) |
| April 8, 2015 | NCT02411773 | Sympatholysis in Chronic Kidney Disease | Emory University | Phase 1 | Recruiting | Chronic Kidney Disease | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02411773) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Ono Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/ono-pharmaceutical-co-ltd) | 1 |
| University of Campinas, Brazil | 1 |
| [Beijing Continent Pharmaceutical Co, Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-continent-pharmaceutical-co-ltd) | 1 |
| Consun Pharmaceutical Group | 1 |
| Cajal Therapeutics Inc. | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Qianfoshan Hospital | 1 |
| Emory University | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Adia Med of Winter Park LLC | 1 |
| Regend Therapeutics | 1 |
| Boston Medical Center | 1 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 1 |
| Pulmongene Ltd. | 1 |
| University of California, Los Angeles | 1 |
| EicOsis Human Health Inc. | 1 |
| Klotho Sciences Australia Pty Ltd. | 1 |
| [Biohaven Therapeutics Ltd.](https://specstream.ai/data/clinical-trials/company/biohaven-therapeutics-ltd) | 1 |
| Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Ohio State University Comprehensive Cancer Center | 1 |
| [Shandong Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shandong-suncadia-medicine-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 10 |
| China | 6 |
| Australia | 3 |
| Germany | 2 |
| Japan | 1 |
| Brazil | 1 |
| Belgium | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
- [Estate planning law firms in the United States](https://specstream.ai/data/businesses/estate-planning-law-firms/united-states)
- [Law firms in the United States](https://specstream.ai/data/businesses/law-firms/united-states)
- [Psychology practices in the United States](https://specstream.ai/data/businesses/psychology-practices/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
